Category Archives: Cancer

Clinical Trial One-Time MS Treatment Appears Promising for Sustaining Remission

A recent clinical trial sponsored by the National Institute of Allergy and Infectious Diseases shows promising 5-year evidence of sustained remission for people with multiple sclerosis (MS) who are treated with immunosuppressive therapy and an autologous stem cell transplant. For individuals with relapsing-remitting MS, the one-time treatment proved more effective than long-term use of MS drugs currently on the market. The news is encouraging for individuals with the often-debilitating disease, for whom traditional medications are ineffective. In this trial, 69 percent of the participants saw no new brain lesions or worsened neurological disability. Adverse effects of the treatment included infections and a reduction in blood cells due to the high dose of chemotherapy used.

At age 63, Dr. Shiva Vasishta is a neurologist with 38 years of experience, and according to reviews, his patients trust his decisions. Currently, Dr. Vasishta is affiliated with Eastern Neurodiagnostic Associates, a group practice in Voorhees, New Jersey. A graduate of Indira Gandhi Medical College, Dr. Shiva Vasishta did his fellowship in clinical neurophysiology at Tufts Medical Center, his neurology residency at Boston Medical Center and his residency for internal medicine at the Government Medical College and Hospital in Nagpur. Dr. Shiva Vasishta holds an American Board of Psychiatry and Neurology Certification in Neurology and he is Board Certified in Neurology.

Dr. Shiva Vasishta has expertise in treating MS as well as epilepsy, migraine disorders and Alzheimer’s disease. His hospital affiliations include the Medical Center at Princeton, Kennedy Memorial at Stratford-Cherry Hill and Virtua-Memorial Hospital of Burlington.

Dr. Clay B. Siegall is a Lead Fighter against Cancer

Dr. Clay B. Siegall is a trained scientist and a co-founder of Seattle Genetics Inc., a biotechnology company founded in1997 that deals with developing monoclonal antibody therapies for cancer treatment. Dr. Siegall was motivated to establish this biotech powerhouse by his passion for scientific research and innovation and his desire to help cancer patients. He currently serves as the company’s President, CEO, and the board chair. He earned his degree in zoology from the University of Maryland and a doctorate in Genetics from Washington University. Dr. Siegall is the author of more than 70 pharmaceutical papers and has 15 patents to his name.


Dr. Siegall’s impressive journey in biotechnology world


Dr. Siegall’s rich experience in cancer research and development of therapeutic drugs can be traced back to 1988 when he served for three years as a biotechnology fellow at the National Cancer Institute. From 1991 to 1995, Dr.Siegall worked as a senior research investigator with the Bristol-Myers Squibb Pharmaceutical Research Institute. In 1995, he became a Principal Scientist at the same institution before leaving in December 1997 to create Seattle Genetics Inc.


Dr. Siegall was appointed as the interim chairman of Seattle Genetics in 2004. Later that year, he was confirmed as the chairman, a position he has held to date. Dr. Siegall has been the Director of Alder Biopharmaceuticals since 2005 and Ultragenyx Pharmaceuticals since 2014. He is a member of the Fred Hutchinson Cancer Research Business Alliance’s governing council. Dr. Siegall serves as the executive principal of Washington Biotechnology and Biomedical Association. In 2013, Dr. Siegall became the non-executive director of Mirna Therapeutics, Inc.




As the CEO, Dr. Siegall has steered Seattle Genetic to great technological advancements. The company has pursued several licenses aimed at strengthening their ADC technology. They have collaborated with some Biotechnology Corporations, including AbbVie, GlaxoSmithKline, and Genentech to execute the ADC technology, generating over $325 million in the process. Currently, there are about 20 ADCs in clinical developments. Seattle has created a pipeline of innovative therapies, which are used in the treatment of Leukemia and other blood-related cancers and tumors.